Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections.
Antimicrobial susceptibilities were determined for 1,586 isolates of Stenotrophomonas maltophilia from globally diverse medical centers using the Clinical Laboratory Standards Institute broth microdilution method. The combination trimethoprim-sulfamethoxazole (96.0% of isolates susceptible at < or =2 microg/ml trimethoprim and 38 microg/ml sulfamethoxazole) and tigecycline (95.5% of isolates sussceptible at < or =2 microg/ml) were the only antimicrobials tested with >94% susceptibility in all regions. Susceptibility rates for other commonly used were lower than expected and varied geographically. This in vitro data supports tigecycline as a potential candidate for clinical investigations into S. maltophilia infections.
Farrell
David J
DJ
JMI Laboratories, North Liberty, IA 52317, USA. david-farrell@jmilabs.com
Sader
Helio S
HS
Jones
Ronald N
RN
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001208:Asia; D005060:Europe; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology*; D006801:Humans; D066298:In Vitro Techniques; D007843:Latin America; D008826:Microbial Sensitivity Tests / Q000379:methods; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D009656:North America; D020615:Stenotrophomonas maltophilia / Q000187:drug effects* / Q000302:isolation & purification; D000078304:Tigecycline
D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline